Form 4: Moderna CEO Stephane Bancel Reports Stock Vesting and Tax Withholding

Moderna's CEO, Stephane Bancel, reported the vesting of performance-based restricted stock units and the subsequent withholding of shares to cover tax obligations.

Summary

• On February 12, 2025, Stephane Bancel, CEO of Moderna, Inc., reported the vesting of 13,233 performance-based restricted stock units.
• Simultaneously, 6,400 shares were withheld to satisfy tax obligations related to the vesting.
• The price per share for the tax withholding was $30.93.
• Following these transactions, Bancel directly owns 5,493,897 shares of Moderna common stock.
• Bancel also has indirect beneficial ownership of 9,050,372 shares through Boston Biotech Ventures, LLC and 6,564,880 shares through OCHA LLC, but disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions, with no inherent positive or negative implications for the company's performance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies like Moderna. It provides transparency to investors regarding the CEO's holdings and transactions.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• Tax withholding practices related to stock vesting are standard across publicly traded companies.
• The reporting of beneficial ownership through entities like LLCs is a common practice among high-net-worth individuals.

Stakeholder Impact

• The filing provides transparency to shareholders regarding executive compensation and stock ownership.
• The transactions have a minimal direct impact on employees, customers, suppliers, or creditors.

Key Dates